Intrust Bank NA Has $1.19 Million Stock Holdings in Centene Co. (NYSE:CNC)

Intrust Bank NA cut its holdings in shares of Centene Co. (NYSE:CNC) by 1.0% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 15,989 shares of the company’s stock after selling 162 shares during the quarter. Intrust Bank NA’s holdings in Centene were worth $1,187,000 at the end of the most recent quarter.

Other hedge funds have also made changes to their positions in the company. Sandy Spring Bank grew its stake in Centene by 10.1% in the fourth quarter. Sandy Spring Bank now owns 1,629 shares of the company’s stock valued at $121,000 after purchasing an additional 150 shares in the last quarter. Signaturefd LLC lifted its stake in Centene by 1.5% in the third quarter. Signaturefd LLC now owns 10,456 shares of the company’s stock valued at $720,000 after acquiring an additional 158 shares during the last quarter. First Bank & Trust increased its stake in shares of Centene by 4.1% during the 4th quarter. First Bank & Trust now owns 4,154 shares of the company’s stock worth $308,000 after purchasing an additional 162 shares during the last quarter. Blue Trust Inc. lifted its stake in shares of Centene by 7.2% in the 4th quarter. Blue Trust Inc. now owns 2,454 shares of the company’s stock valued at $169,000 after purchasing an additional 164 shares during the last quarter. Finally, Cornercap Investment Counsel Inc. raised its holdings in Centene by 0.5% during the fourth quarter. Cornercap Investment Counsel Inc. now owns 32,396 shares of the company’s stock valued at $2,404,000 after buying an additional 174 shares in the last quarter. 93.63% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In related news, Director Lori Jean Robinson sold 10,000 shares of the company’s stock in a transaction on Tuesday, February 13th. The shares were sold at an average price of $77.41, for a total value of $774,100.00. Following the completion of the transaction, the director now directly owns 11,455 shares of the company’s stock, valued at approximately $886,731.55. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In other news, Director Lori Jean Robinson sold 10,000 shares of the firm’s stock in a transaction that occurred on Tuesday, February 13th. The shares were sold at an average price of $77.41, for a total transaction of $774,100.00. Following the completion of the transaction, the director now directly owns 11,455 shares of the company’s stock, valued at approximately $886,731.55. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, President Kenneth J. Fasola sold 12,000 shares of the business’s stock in a transaction dated Wednesday, February 7th. The stock was sold at an average price of $75.07, for a total transaction of $900,840.00. Following the sale, the president now directly owns 235,365 shares in the company, valued at $17,668,850.55. The disclosure for this sale can be found here. Corporate insiders own 0.29% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the company. StockNews.com upgraded Centene from a “buy” rating to a “strong-buy” rating in a report on Monday. Cantor Fitzgerald reiterated an “overweight” rating and issued a $90.00 target price on shares of Centene in a report on Thursday, April 4th. Barclays began coverage on shares of Centene in a report on Wednesday, March 6th. They set an “overweight” rating and a $101.00 price target for the company. Wells Fargo & Company boosted their price objective on Centene from $89.00 to $93.00 and gave the stock an “overweight” rating in a research report on Monday, April 15th. Finally, Stephens reaffirmed an “equal weight” rating and issued a $85.00 price target (down from $92.00) on shares of Centene in a research report on Thursday, March 21st. Five equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Centene currently has a consensus rating of “Moderate Buy” and an average target price of $85.25.

Centene Trading Down 1.0 %

Shares of Centene stock traded down $0.77 during trading on Tuesday, reaching $73.06. 460,812 shares of the company were exchanged, compared to its average volume of 3,086,983. The firm has a market capitalization of $39.08 billion, a price-to-earnings ratio of 14.68, a P/E/G ratio of 0.92 and a beta of 0.38. The business has a 50-day moving average price of $76.22 and a 200-day moving average price of $74.85. The company has a quick ratio of 1.11, a current ratio of 1.17 and a debt-to-equity ratio of 0.66. Centene Co. has a twelve month low of $60.83 and a twelve month high of $81.42.

Centene (NYSE:CNC) last posted its earnings results on Friday, April 26th. The company reported $2.26 earnings per share for the quarter, topping the consensus estimate of $2.09 by $0.17. Centene had a net margin of 1.76% and a return on equity of 14.19%. The company had revenue of $40.41 billion for the quarter, compared to analyst estimates of $36.43 billion. During the same period last year, the business posted $2.11 earnings per share. The business’s revenue for the quarter was up 3.9% compared to the same quarter last year. Sell-side analysts anticipate that Centene Co. will post 6.75 EPS for the current fiscal year.

Centene Company Profile

Centene Corporation operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States. The company operates through Medicaid, Medicare, Commercial, and Other segments. The Medicaid segment offers health plan coverage, including medicaid expansion, aged, blind, disabled, children's health insurance program, foster care, medicare-medicaid plans, long-term services and support.